Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03858920 · ClinicalTrials.gov registry record
The Liver in the World Trade Center Health Program General Responder Cohort and Controls
A clinical trial of NASH - Nonalcoholic Steatohepatitis and Steatosis of Liver, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 340
- Enrollment target
- 1
- Study location
NCT03858920 is a study of NASH - Nonalcoholic Steatohepatitis and Steatosis of Liver that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 340 participants, above the 256-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03858920, a study of NASH - Nonalcoholic Steatohepatitis and Steatosis of Liver, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 340 participants
- Enrollment target
- 1
- Study location
Study Summary
This project investigates whether exposure to the World Trade Center Attack is a risk factor for liver injury.
Conditions Studied
Interventions
- DEVICE Fibroscan of Liver
- PROCEDURE Low-dose non-contrast CT
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2018-05-08 |
| Est. Completion | 2021-06-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03858920
The ClinicalTrials.gov registry entry for NCT03858920 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 256-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (33% higher). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Fibroscan of Liver is the first listed.
NCT03858920 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03858920 about?
NCT03858920 is a clinical study titled "The Liver in the World Trade Center Health Program General Responder Cohort and Controls". This project investigates whether exposure to the World Trade Center Attack is a risk factor for liver injury.
What is the current status of trial NCT03858920?
This trial is currently completed. The enrollment target is 340 participants. The study started on 2018-05-08. Estimated completion is 2021-06-11.
What conditions does trial NCT03858920 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis, Steatosis of Liver.
What interventions are being tested in trial NCT03858920?
The interventions under investigation include: Fibroscan of Liver (DEVICE), Low-dose non-contrast CT (PROCEDURE).
Who is sponsoring clinical trial NCT03858920?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03858920 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
RECRUITING
-
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
RECRUITING · NA
-
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
RECRUITING · NA
-
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
RECRUITING · Phase 3
-
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
RECRUITING · Phase 3
-
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.